Marathon Asset Management Ltd Has $14.33 Million Position in Bio-Rad Laboratories, Inc. $BIO

Marathon Asset Management Ltd cut its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 8.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 47,292 shares of the medical research company’s stock after selling 4,626 shares during the quarter. Marathon Asset Management Ltd’s holdings in Bio-Rad Laboratories were worth $14,329,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Danske Bank A S bought a new stake in Bio-Rad Laboratories in the 4th quarter valued at $30,000. Geneos Wealth Management Inc. boosted its stake in Bio-Rad Laboratories by 115.2% in the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 76 shares during the period. Farther Finance Advisors LLC boosted its stake in Bio-Rad Laboratories by 76.9% in the 4th quarter. Farther Finance Advisors LLC now owns 184 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 80 shares during the period. Financial Management Professionals Inc. bought a new stake in Bio-Rad Laboratories in the 4th quarter valued at $61,000. Finally, CWM LLC boosted its stake in Bio-Rad Laboratories by 82.0% in the 3rd quarter. CWM LLC now owns 202 shares of the medical research company’s stock valued at $57,000 after purchasing an additional 91 shares during the period. 65.24% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Stock Performance

NYSE:BIO opened at $280.56 on Wednesday. The stock has a fifty day moving average price of $273.53 and a 200-day moving average price of $292.69. The company has a market cap of $7.51 billion, a price-to-earnings ratio of 46.22 and a beta of 1.06. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.37 and a current ratio of 3.21. Bio-Rad Laboratories, Inc. has a fifty-two week low of $211.43 and a fifty-two week high of $343.12.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, April 30th. The medical research company reported $1.89 earnings per share for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). The company had revenue of $592.10 million for the quarter, compared to the consensus estimate of $589.91 million. Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%. The business’s revenue was up 1.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.54 earnings per share. As a group, equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on BIO. Citigroup downgraded Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and reduced their price target for the company from $375.00 to $300.00 in a research note on Tuesday, April 7th. Royal Bank Of Canada began coverage on Bio-Rad Laboratories in a research note on Friday, May 15th. They issued an “outperform” rating and a $320.00 price target for the company. Wells Fargo & Company reduced their price target on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating for the company in a research note on Friday, May 1st. Weiss Ratings downgraded Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $303.33.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.